Global Landscape of follow-on biologics

Current knowledge is limited about which manufacturers are active in the global field of biopharmaceutical product development and how many unique follow-on biologics are approved in global markets. In 2022, Exon Consultancy investigated the global landscape of follow-on biologics manufacturers through a cross-sectional overview.

We screened national drug databases to identify follow-on biologics and their manufacturers approved in 15 countries in Asia, Africa, Latin America and the rest of the world, as well as five major biosimilar markets: the European Union (including the UK), USA, Canada, Australia and Japan. Our findings have been published in a peer-reviewed scientific journal, which aims to contribute to discussions on creating more transparency about global approvals of follow-on biologics and promote access to high-quality biosimilars in countries around the world.

More information about the project can be found here.

Client:
IFPMA

Date of completion:
2022